Reactions 1664, p13 - 12 Aug 2017 Acute profound thrombocytopenia: case reports A 53-year-old man developed acute profound thrombocytopenia during therapy with abciximab [route and dosage not stated]. The man with acute chest pain was diagnosed with non ST elevation myocardial infarction. Subsequently, he underwent percutaneous coronary intervention with abciximab infusion and heparin. However, he developed acute profound thrombocytopenia. His platelet count was notes as less than 20000/L within nine hours of abciximab infusion [outcome not stated]. Author comment: "Abciximab (c7E3 Fab) is one of the three potent intravenous glycoprotein IIb/IIIa receptor inhibitors (along with eptifibatide and tirofiban) that have shown significant positive outcomes when used in patients with intracoronary thrombus. However, major side effects have been reported with its use including hypotension, major bleeding and thrombocytopenia." Golden T, et al. Abciximab-induced acute profound thrombocytopenia postpercutaneous coronary intervention. BMJ Case Reports 2017: 221182, Jan 2017. Available from: URL: http://doi.org/10.1136/bcr-2017-221182 [Summarised from an abstract] - USA 803262699 0114-9954/17/1664-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 12 Aug 2017 No. 1664
Reactions Weekly – Springer Journals
Published: Aug 12, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera